TFM
FBRX icon

TFC Financial Management’s Forte Biosciences FBRX Stock Holding History

TFC Financial Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20
Closed -$18K – 579
2020
Q4 		$18K Hold
20
– – 0.01% 260
2020
Q3 		$24K Buy
+20
New +$13.3K 0.01% 225

Other funds holding FBRX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TFC Financial Management's FBRX Position: Q1 2021 in Review

TFC Financial Management sold out of Forte Biosciences (FBRX) in Q1 2021, closing a stake of 20 shares — an estimated $18K sold.

TFC Financial Management first reported a position in FBRX in Q3 2020 and held it in 2 quarters. The position peaked at $24K in Q3 2020. 62 funds tracked by Wall St. Rank hold FBRX as of Q1 2021.

  • TFC Financial Management reported no remaining Forte Biosciences position as of Q1 2021 after selling out during the quarter.
  • TFC Financial Management sold 20 Forte Biosciences shares in Q1 2021, an estimated $18K.
  • TFC Financial Management first reported a position in Forte Biosciences in Q3 2020 and held it in 2 quarters.
  • TFC Financial Management's Forte Biosciences position peaked at $24K in Q3 2020.
  • 62 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2021.

Based on TFC Financial Management's 13F filing for Q1 2021, filed 3 May 2021.